Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Enanta Pharmaceuticals, Inc. (ENTA) Healthcare & Pipeline Overview

Enanta Pharmaceuticals, Inc. is a biotechnology firm specializing in small molecule drugs targeting viral infections and liver diseases. With a focus on respiratory syncytial virus (RSV) and hepatitis B, Enanta operates in a competitive landscape, leveraging collaborations to advance its drug development pipeline and address unmet medical needs.

What Is the Investment Thesis for ENTA?

Enanta Pharmaceuticals presents a focused investment opportunity within the biotechnology sector, driven by its specialization in small molecule drugs targeting viral infections and liver diseases. Key to the investment thesis is the potential success of its RSV program, a market with significant unmet needs. The company's collaborative agreement with Abbott Laboratories provides a steady revenue stream and validation of its research capabilities. However, the company's negative profit margin of -106.8% highlights the risks associated with biotech investments, particularly the high costs of drug development and clinical trials. Successful clinical trial outcomes and regulatory approvals for its pipeline candidates are critical for future growth and shareholder value. Monitoring the progress of its RSV and HBV programs, as well as the financial performance of its Abbott collaboration, will be essential for assessing the long-term investment viability.

Based on FMP financials and quantitative analysis

ENTA Key Highlights

Market Cap of $377M reflects the company's current valuation in the biotechnology sector.

• Profit Margin of -106.8% indicates ongoing investment in research and development, typical for biotech companies in the drug development phase.
• Gross Margin of 100.0% demonstrates the potential profitability of its existing collaborations and licensed products.
• Beta of 1.00 suggests the stock's volatility is in line with the overall market.
• No Dividend reflects the company's focus on reinvesting earnings into research and development.

Who Are ENTA's Competitors?

ENTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENTA's Key Strengths?

Specialized expertise in small molecule drug discovery.

• Strong focus on viral infections and liver diseases.
• Established collaboration with Abbott Laboratories.
• Proprietary drug development platform.

What Are ENTA's Weaknesses?

Negative profit margin (-106.8%).

• Reliance on partnerships for commercialization.
• High research and development costs.
• Limited product portfolio.

What Could Drive ENTA Stock Higher?

Clinical trial results for RSV program.

• Regulatory submissions for HBV candidate.
• Progress in collaborative development with Abbott Laboratories.
• Expansion of research and development pipeline.

What Are the Key Risks for ENTA?

Financial-distress signal — its Altman Z-Score of -0.65 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-59.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for drug candidates.
• Regulatory approval delays.
• Competition from other pharmaceutical companies.
• High research and development costs.
• Dependence on partnerships for commercialization.

What Are the Growth Opportunities for ENTA?

• Expansion of RSV Program: Enanta's respiratory syncytial virus (RSV) program represents a significant growth opportunity. Successful development and commercialization of its RSV candidate could generate substantial revenue. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory approvals, potentially materializing within the next 3-5 years.
• Advancement of HBV Program: Enanta's hepatitis B virus (HBV) program offers another avenue for growth. Chronic HBV infection affects millions worldwide, creating a substantial market for new and effective treatments. The company's HBV candidate aims to address the limitations of current therapies. Positive clinical trial results and regulatory approval could lead to significant market penetration and revenue generation over the next 5-7 years.
• Strategic Partnerships and Collaborations: Enanta can leverage strategic partnerships and collaborations to expand its pipeline and market reach. Collaborating with larger pharmaceutical companies or other biotech firms can provide access to additional resources, expertise, and distribution channels. These partnerships can accelerate the development and commercialization of its drug candidates, contributing to long-term growth. The timing and impact of these collaborations are contingent on specific agreements and market conditions.
• Expansion into New Therapeutic Areas: Enanta has the potential to expand its research and development efforts into new therapeutic areas beyond viral infections and liver diseases. Leveraging its expertise in small molecule drug discovery, the company could target other areas with unmet medical needs, such as autoimmune disorders or oncology. This diversification strategy could broaden its revenue base and reduce its reliance on specific therapeutic areas. The timeline for this expansion is dependent on strategic decisions and resource allocation.
• Geographic Expansion: Enanta can pursue geographic expansion to increase its market presence and revenue streams. Currently focused on the US market, the company could expand into Europe, Asia, and other regions with significant unmet medical needs. This expansion would require establishing partnerships, navigating regulatory requirements, and building distribution networks. The timeline for geographic expansion depends on market analysis, regulatory approvals, and resource availability.

What Are ENTA's Competitive Advantages?

• Proprietary small molecule drug discovery platform.
• Strong intellectual property portfolio with patents on drug candidates.
• Established collaboration with Abbott Laboratories.
• Expertise in viral infections and liver diseases.

What Does ENTA Do?

Enanta Pharmaceuticals, Inc., founded in 1995 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to the discovery and development of small molecule drugs. The company focuses on addressing unmet needs in viral infections and liver diseases. Enanta's research and development efforts are primarily directed toward respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus, and hepatitis B virus (HBV). Their approach involves identifying and developing novel compounds that can effectively combat these viral targets. A significant aspect of Enanta's business strategy is its collaborative development and license agreement with Abbott Laboratories. This collaboration focuses on identifying, developing, and commercializing HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir, for the treatment of chronic hepatitis C virus. This partnership has been crucial in advancing Enanta's research and bringing potential treatments to market. Enanta's pipeline represents a commitment to addressing significant public health challenges through innovative drug development. With a team of 131 employees, Enanta operates with a focus on scientific excellence and strategic partnerships to drive its mission forward.

What Products and Services Does ENTA Offer?

• Discovers small molecule drugs for viral infections.
• Develops treatments for liver diseases.
• Targets respiratory syncytial virus (RSV).
• Researches treatments for SARS-CoV-2.
• Develops drugs for human metapneumovirus.
• Works on therapies for hepatitis B virus (HBV).

How Does ENTA Make Money?

• Develops and patents small molecule drugs.
• Out-licenses drug candidates to larger pharmaceutical companies.
• Generates revenue from royalties on partnered drugs.
• Receives milestone payments upon achievement of development goals.

What Industry Does ENTA Operate In?

Enanta Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for antiviral drugs and treatments for liver diseases is substantial, driven by the global prevalence of viral infections and liver disorders. Key trends include the development of novel small molecule drugs and advancements in targeted therapies. Enanta's focus on RSV and HBV positions it within high-growth areas, but it faces competition from larger pharmaceutical companies and other biotech firms pursuing similar targets.

Who Are ENTA's Key Customers?

• Pharmaceutical companies (e.g., Abbott Laboratories).
• Patients suffering from viral infections.
• Healthcare providers prescribing antiviral medications.

Company Profile

Enanta Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Jay R. Luly. ENTA has traded publicly since 2013.

Return on equity for Enanta Pharmaceuticals, Inc. stands at -59.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.84 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

ENTA Valuation & Market Position

With a $377M market cap, Enanta Pharmaceuticals, Inc. sits in the small-cap segment of the market. Relative to its peer group, ENTA's quantitative score of 14/100 is below the peer average of 76/100.

Quarterly Financial Performance: Enanta Pharmaceuticals, Inc.

Revenue for Enanta Pharmaceuticals, Inc. came in at $14.4M during Q2 2026, a 16.3% contraction versus the preceding quarter. The company recorded a net loss of $19.5M, with diluted EPS of $-0.67. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, ENTA averaged $-0.60 in diluted EPS.

Enanta Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.65 places it in the distress zone, a signal of elevated financial risk.

Enanta Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.8% above estimates on average.

Wall Street analysts project Enanta Pharmaceuticals, Inc. revenue of about $67.3M for fiscal 2026, with EPS near $-2.30. The estimate reflects 3 contributing analysts.

Over the past six months, Enanta Pharmaceuticals, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 120K shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.

ENTA Financials

ENTA Latest News

ENTA Analyst Consensus

ENTA MoonshotScore

Common Questions About ENTA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources